Analyst Ratings For aTyr Pharma (NASDAQ:LIFE)
Today, aTyr Pharma (NASDAQ:LIFE) stock was downgraded by JPMorgan Chase & Co. from Neutral to Underweight.
Some recent analyst ratings include
- 2/14/2018-JPMorgan Chase & Co. was Downgraded by analysts at JPMorgan Chase & Co. from a “Neutral ” rating to a ” Underweight” rating.
- 9/7/2017-Piper Jaffray Companies initiated coverage with a Overweight rating.
- 3/31/2016-William Blair was Downgraded by analysts at William Blair from a “Outperform ” rating to a ” Market Perform” rating.
Recent Insider Trading Activity For aTyr Pharma (NASDAQ:LIFE)
aTyr Pharma (NASDAQ:LIFE) has insider ownership of 33.30% and institutional ownership of 58.00%.
- On 2/8/2018 Ashraf Amanullah, Insider, sold 1,402 with an average share price of $3.40 per share and the total transaction amounting to $4,766.80.
- On 8/31/2017 John Mendlein, CEO, bought 37,736 with an average share price of $2.65 per share and the total transaction amounting to $100,000.40.
- On 8/31/2017 Paul Schimmel, Director, bought 94,336 with an average share price of $2.65 per share and the total transaction amounting to $249,990.40.
- On 4/24/2017 John Mendlein, CEO, bought 124 with an average share price of $3.00 per share and the total transaction amounting to $372.00.
- On 4/20/2017 John Mendlein, CEO, bought 2,552 with an average share price of $3.00 per share and the total transaction amounting to $7,656.00.
- On 12/21/2016 Paul Schimmel, Director, bought 25,000 with an average share price of $2.28 per share and the total transaction amounting to $57,000.00.
- On 12/20/2016 Ashraf Amanullah, VP, bought 11,000 with an average share price of $2.25 per share and the total transaction amounting to $24,750.00.
Recent Trading Activity for aTyr Pharma (NASDAQ:LIFE)
Shares of aTyr Pharma closed the previous trading session at 3.30 down -0.20 5.71% with 10758 shares trading hands.